Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal

Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More